The compressed new drug application timelines, along with the priority review puts the commercial launch of Global Blood Therapeutics' voxelotor during Q1 of 2020, assuming a first pass approval, which is about two quarters ahead of prior estimates, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Another Bear Thesis Takes the Back Seat." The analyst expects the shares to "recover some of their lost mojo," which he believes was driven by the uncertainty surrounding a potential FDA panel meeting considering voxelotor's new chemical entity status. The decision not to hold a panel "potentially represents our bull case scenario for voxelotor," says Chattopadhyay. He keeps a Buy rating on Global Blood Therapeutics with a $150 price target. The stock in premarket trading is up 16%, or $7.72, to $55.21.